Perspective Therapeutics, Inc.
CATXAMEXHealthcareMedical - Devices
Regular session
$3.235
−$0.065 · -1.97%
CATX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
14
Overpriced
Momentum
34
Weakening
Sentiment
48
Mixed
Risk resilience
25
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websitePerspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Johan Spoor
- Listed since
- Nov 10, 2005
- Employees
- 165
Market position
Day range
Current $3.235
52-week range
Current $3.235
- Open
- $3.32
- Previous close
- $3.30
- Volume
- 251.39K
- 0.16× average
- Average volume
- 1.62M
- Average daily volume
- Market cap
- 368.94M USD
- Beta
- 1.8
- Market reference 1
- 50-day average
- $3.1006
- +4.33% above average
- 200-day average
- $3.5195
- -8.08% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -2.26×
- P/B (TTM)
- 0×
- P/S (TTM)
- 902.05×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -611.98%
- Operating margin
- -30619.07%
- Net margin
- -28467.97%
Financial health
- Debt / equity
- 0.01×
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$11.50
255.49% upsideCATX news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 17, 2024 | 1:10 | — | — |
Stock split | Aug 17, 2005 | 1:30 | — | — |
Stock split | Jul 6, 1988 | 1:20 | — | — |
Effective Jun 17, 2024
1:10
Effective Aug 17, 2005
1:30
Effective Jul 6, 1988
1:20
CATX peers
Continue in GoAI
Research CATXresearch.disclaimer